Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02987166 | HDCRT Plus Pembrolizumab in Advanced Malignancies(UVA-AM-001) | completed | Phase 1 | 21 | James Larner, MDOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05947474 | ORB-011 In Patients With Advanced Solid Tumors(ORB) | completed | Phase 1 | 55 | Orionis Biosciences IncINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06253195 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 33 | BeOne MedicinesINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06422520 | A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 63 | BeOne MedicinesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT06242691 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) | completed | Phase 1 / Phase 2 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jun 5, 2026 | clinicaltrials |
| NCT06235983 | A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT05052268 | XTX202 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 95 | Xilio Development, Inc.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT03611595 | Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 15 | Peter ZageOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05173142 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 190 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02797795 | A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers | completed | Phase 1 | 78 | Neovia Oncology Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04322006 | A Phase I/II Study of TJ004309 for Advanced Solid Tumor | completed | Phase 1 / Phase 2 | 225 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05038839 | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors | completed | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05162755 | S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers | completed | Phase 1 | 41 | Institut de Recherches Internationales ServierOTHER | 2 | May 12, 2026 | clinicaltrials |
| NCT05076396 | PM14 Administered Intravenously to Patients With Advanced Solid Tumors | completed | Phase 1 | 126 | PharmaMarINDUSTRY | 3 | May 11, 2026 | clinicaltrials |
| NCT05387928 | A Study of KL340399 in Patients With Advanced Solid Tumors | completed | Phase 1 | 21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05549804 | A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04457778 | First in Human Study of M6223 | completed | Phase 1 | 58 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT05824663 | A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 17 | Harbour BioMed US, Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07554196 | A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | Huahui HealthINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01787500 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | completed | Phase 1 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06308263 | Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) | completed | Phase 1 | 12 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03317743 | Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors | completed | Phase 1 | 32 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04174716 | Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)(VASTUS) | completed | Phase 1 / Phase 2 | 108 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors(iintune-1) | completed | Phase 1 / Phase 2 | 248 | TakedaINDUSTRY | 11 | Apr 8, 2026 | clinicaltrials |
| NCT04050709 | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | completed | Phase 1 | 16 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05148325 | Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors | completed | Phase 1 | 28 | Bio-Thera SolutionsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02133625 | A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05727839 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | completed | Phase 1 | 19 | Immorna Biotherapeutics, Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT04158336 | A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors | completed | Phase 1 | 274 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04423029 | A Study of DF6002 Alone and in Combination With Nivolumab | completed | Phase 1 | 170 | Dragonfly TherapeuticsINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT06108479 | Study of DF6215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dragonfly TherapeuticsINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06056024 | A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus | completed | Phase 1 | 47 | Boehringer IngelheimINDUSTRY | 4 | Mar 17, 2026 | clinicaltrials |
| NCT03725436 | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04261413 | Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 16 | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.INDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05735366 | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Chugai PharmaceuticalINDUSTRY | 2 | Mar 10, 2026 | clinicaltrials |
| NCT04695327 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy(TUNIMO) | completed | Phase 1 | 32 | TILT Biotherapeutics Ltd.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02617277 | Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04238819 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | completed | Phase 1 / Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | completed | Phase 1 / Phase 2 | 97 | BeiGeneINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT05800964 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | AmgenINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05478486 | Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours | completed | Phase 1 | 7 | Godavari Biorefineries LimitedOTHER | 1 | Feb 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2026source: clinicaltrials